Protalix BioTherapeutics, Inc. (NYSE:PLX - Free Report) - Equities research analysts at HC Wainwright lifted their Q1 2025 EPS estimates for shares of Protalix BioTherapeutics in a research report issued to clients and investors on Monday, April 28th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of $0.08 for the quarter, up from their prior estimate of $0.03. HC Wainwright has a "Buy" rating and a $15.00 price objective on the stock. The consensus estimate for Protalix BioTherapeutics' current full-year earnings is $0.01 per share. HC Wainwright also issued estimates for Protalix BioTherapeutics' Q2 2025 earnings at $0.11 EPS, Q3 2025 earnings at $0.12 EPS, Q4 2025 earnings at $0.13 EPS and FY2025 earnings at $0.45 EPS.
Separately, StockNews.com lowered Protalix BioTherapeutics from a "strong-buy" rating to a "buy" rating in a report on Thursday, March 20th.
Check Out Our Latest Analysis on PLX
Protalix BioTherapeutics Price Performance
NYSE:PLX traded down $0.09 during mid-day trading on Thursday, hitting $2.75. The company's stock had a trading volume of 467,379 shares, compared to its average volume of 476,295. The business's fifty day moving average is $2.52 and its two-hundred day moving average is $2.12. The stock has a market cap of $218.43 million, a price-to-earnings ratio of -21.12 and a beta of -0.05. Protalix BioTherapeutics has a 1 year low of $0.82 and a 1 year high of $3.10.
Institutional Trading of Protalix BioTherapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC purchased a new stake in shares of Protalix BioTherapeutics during the 3rd quarter worth about $44,000. Sanctuary Advisors LLC purchased a new position in Protalix BioTherapeutics during the third quarter worth approximately $38,000. PFG Investments LLC acquired a new stake in Protalix BioTherapeutics in the fourth quarter valued at approximately $39,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Protalix BioTherapeutics in the fourth quarter valued at approximately $35,000. Finally, Prudential Financial Inc. acquired a new position in shares of Protalix BioTherapeutics during the 4th quarter worth approximately $68,000. Institutional investors and hedge funds own 16.53% of the company's stock.
Protalix BioTherapeutics Company Profile
(
Get Free Report)
Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.
Featured Stories
Before you consider Protalix BioTherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protalix BioTherapeutics wasn't on the list.
While Protalix BioTherapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
